For Pharmacists: Evolution of HER2-Targe...

Do you know how many different types of anti-HER2 therapies are in clinical trials for gastroesophageal adenocarcinoma (GEA)? Credit available for this activity expires: 02/27/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/breaking-grou ... Show More

Transforming CLL care: measurable residual disease (MRD) guided stopping, smart triplet selection, and next‑gen Bruton tyrosine kinase (BTKs)—practical insights. Credit available for this activity expires: 02/19/27 Earn Credit / Learning Objectives & Disclosures: https://www.meds ... Show More

Are you up to date on the management of extensive-stage small cell lung cancer (ES-SCLC)? Credit available for this activity expires: 2/20/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/quick-talk-es-sclc-what-community-clinicians-need-kn ... Show More

An interview with Dr. Beverly Moy from Massachusetts General Hospital in Boston, MA, lead author on "Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation ... Show More

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ... Show More

Are you using liquid biopsies in your practice? Join Drs Benjamin Schlechter and Pashtoon Kasi as they review the latest clinical applications of ctDNA and liquid biopsies in colorectal cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www. ... Show More

Dr. Manish Shah discusses the first ASCO guideline for advanced gastroesophageal cancer. He addresses biomarker testing to help guide therapy - including HER2 testing, mismatch repair testing, and assessment of PD-L1 expression. Dr. Shah then reviews the evidence-based recommenda ... Show More

Dr. Dwight Owen presents the first update to the ASCO living guideline on stage IV NSCLC with driver alterations. He identifies the latest trials that informed this update, and the updated evidence-based options for second- or later-line therapies for patients with advanced non-s ... Show More

An interview with Dr. Sharon Giordano from the University of Texas MD Anderson Cancer Center in Houston, TX, and Dr. Nancy Davidson from Fred Hutchinson Cancer Research Center and the University of Washington in Seattle, WA, co-chairs on "Systemic Therapy for Advanced HER2-Positi ... Show More

<p>Are you up-to-date on the latest lipid-lowering therapies? Dr Ray provides an update.</p> <p>Credit available for this activity expires: 12/27/23<br /> Earn Credit / Learning Objectives & Disclosures: <a href= "https://www.medscape.org/viewarticle/984904" target="_blank" rel= ... Show More

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody– ... Show More

Dr. Antonio Wolff and Dr. Kim Allison discuss the latest ASCO-CAP guideline update on HER2 testing in breast cancer. This guideline update affirms previous recommendations, and provides commentary based on data from the DESTINY-Breast04 trial. Dr. Wolff and Dr. Allison review the ... Show More